Therefore, targeting other members in this ligand-receptor subgroup such as TACI, either alone or in combination with BCMA-targeting therapies, might achieve better clinical efficacy or improve the treatment outcome for MM patients. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.